CLINICAL_TRIALS
withdrawal
· 2023-09-28
Clinical Trial Update: The Effect of a New Antioxidant Combination (ASTED) on Mild Thyroid Eye Disease (TED) [Phase 2, Phase 3]
Summary
A study evaluating an antioxidant combination (ASTED) for Thyroid Eye Disease was withdrawn during Phase 2/Phase 3.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Iran University of Medical Sciences | Conditions: Thyroid Eye Disease | Phase 2, Phase 3 | Status: WITHDRAWN